Reviews/Vitamin B12/Vitamin B12 halts cognitive decline
Neurocognition · VITB12-NEURO-02 · v2
Borderline: within 4 points of the Doubtful/Refuted boundary, so a re-grade could land either side.
The claim is that vitamin B12 keeps thinking sharp as people age. The clearest test in this corpus gave B12 on its own to older adults and found it did not stop cognitive decline [12], and a second trial that added folic acid in people with mild memory problems reached the same null result [11]. A large trial in Alzheimer's disease also found no benefit for thinking [3], and a pooled analysis found brain shrinkage slowed while cognition did not change [14]. The trials that looked positive [5][7][10][16] all used B12 mixed with other B vitamins, or only helped a specific slice of people, so none of them show that B12 itself is what worked. Because the most on-point trials came back negative and the encouraging signals are indirect or narrow, the panel judged the broad claim as leaning false.
The single B12-monotherapy RCT in older diabetic adults found no prevention of cognitive decline over 27 months despite lowering methylmalonic acid and homocysteine [12], and the B12-plus-folic-acid RCT in older MCI patients with elevated homocysteine showed no significant difference in CDR sum-of-boxes or any secondary cognitive outcome at 24 months [11]. A large AD trial found the regimen lowered homocysteine but had no effect on ADAS-cog or any secondary measure [3], and a pooled post-hoc analysis of 545 MCI participants found B vitamins slowed whole-brain atrophy (P = 0.003) yet did not affect CDR-global, CDR-SOB, memory or executive function [14]. The positive results are combined-regimen or conditional: benefit confined to participants with baseline homocysteine above the median [5], a modest effect in community-dwelling distressed older adults on folic acid plus B12 (d ≈ 0.15–0.18) [7], MoCA gains in AD patients [10], and an observational treatment study in cognitively impaired patients [16]. Much of the corpus is repeated re-analysis of the single VITACOG cohort [1][4][5][8]. The contested point: The division is between the direct, on-point B12-containing trials, which are null [11][12], and the encouraging but indirect signals, which appear only for combined B-vitamin regimens or specific subgroups such as elevated homocysteine [5] or high DHA status [8][15]. The surrogate endpoint compounds the split: brain atrophy improves while cognition does not [14].
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Vitamin B12, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Intervention confound: nearly all trials co-administer folic acid ± B6, so no effect can be attributed to B12 specifically; the only B12-monotherapy RCT [12] is null.
Population mismatch: the corpus is dominated by MCI [1][5][6][11][20] and AD [3][10] (treating existing impairment), not primary prevention in general older adults as the claim states.
Where it remains uncertain. Positive results exist only for combined regimens or subgroups defined by high homocysteine [5], high DHA [8], or non-aspirin use [14], so they cannot isolate B12 or support general primary prevention.
Aleatory
Several trials are small (e.g. N=152 [6], N=120 [10]) and [11] notes the cognitive decline in the placebo group over two years was small, leaving little movement for a supplement to prevent against sampling noise.
Epistemic
The one monotherapy RCT [12] was in older diabetics with borderline B12; no trial in this corpus tests B12 alone for primary prevention in unselected healthy older adults.
Inferential
Inferring cognitive protection from slowed brain atrophy [1][4] is undercut by [14], where atrophy improved but cognition did not.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large RCT: no cognitive benefit despite effective homocysteine lowering.
“This regimen of high-dose B vitamin supplements does not slow cognitive decline in individuals with mild to moderate AD.”
Panel auditInternal validity: high · scope of inference: Patients with existing mild-to-moderate Alzheimer disease and normal baseline vitamin/homocysteine levels; treatment not prevention.Key limitations: combined B vitamins not B12 alone · established AD not prevention · normal baseline homocysteine
Positive signal restricted to a high-homocysteine subgroup; combined regimen.
“There was significant benefit of B-vitamin treatment among participants with baseline homocysteine above the median (11.3 µmol/L) in global cognition (Mini Mental State Examination, P < 0.001), episodic memory (Hopkins Verbal Learning Test-delayed recall, P = 0.001) and semantic memory (category fluency, P = 0.037).”
Panel auditInternal validity: medium · scope of inference: Adults ≥70 with MCI; strongest effects in those with elevated baseline homocysteine.Key limitations: combined B vitamins not B12 alone · MCI not general older adults · secondary outcomes · subgroup-driven benefit · small single-centre
Positive cognitive result in community-dwelling older adults, but combined FA+B12 so B12 not isolable.
“Long-term supplementation of daily oral 400 μg FA + 100 μg vitamin B-12 promotes improvement in cognitive functioning after 24 mo, particularly in immediate and delayed memory performance.”
Panel auditInternal validity: medium · scope of inference: Community-dwelling adults 60-74 with elevated psychological distress.Key limitations: combined FA + B12 not B12 alone · small effect sizes · benefit limited to memory domains · distress-selected sample
The primary outcome reported here is rate of whole-brain atrophy; a treatment effect on cognitive decline itself is not reported in this abstract (only an association between atrophy and final cognitive scores).
Panel auditInternal validity: high · scope of inference: Adults over 70 with mild cognitive impairment; brain-atrophy endpoint, not general cognitive-decline prevention.Key limitations: combined B vitamins not B12 alone · MCI not general older adults · atrophy is a proxy not cognition · MRI subset self-selected
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct, on-point B12 trials are null and the positive signals are combined-regimen, subgroup, or surrogate-only, so the generalised claim leans false without being cleanly refuted.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
B12-monotherapy primary-prevention RCT in healthy older adults. Every positive signal is confounded by folic acid or restricted to impaired or subgroup populations; the claim names B12 and prevention in older adults, which nothing here tests directly. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised placebo-controlled trial of B12 alone in cognitively healthy community-dwelling older adults with cognition as the primary endpoint.
Open question: Does B12 supplementation alone prevent cognitive decline in cognitively healthy older adults? Why it is still open: The only monotherapy RCT [12] enrolled older diabetics with borderline B12 and was null; no trial here tests B12 alone in unselected healthy older adults.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19